Drug Price Trends for ALUMINUM

Average Pharmacy Cost for ALUMINUM

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ALUMINUM HYDROXIDE GEL	00536-0091-85	0.01327	ML	2026-07-22
ALUMINUM HYDROXIDE GEL	00536-0091-85	0.01327	ML	2026-06-17
ALUMINUM HYDROXIDE GEL	00536-0091-85	0.01312	ML	2026-05-20
ALUMINUM HYDROXIDE GEL	00536-0091-85	0.01283	ML	2026-04-22
ALUMINUM HYDROXIDE GEL	00536-0091-85	0.01253	ML	2026-03-18
ALUMINUM HYDROXIDE GEL	00536-0091-85	0.01257	ML	2026-02-18

Best Wholesale Price for ALUMINUM

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
DERMELEVE 0.2% CREAM,TOP	Golden State Medical Supply, Inc.	81507-0003-01	120GM	22.39	0.18658	GM	2024-05-15 - 2028-06-14	FSS
DERMELEVE SCALP	Golden State Medical Supply, Inc.	81507-0004-01	89ML	13.99	0.15719	ML	2024-05-15 - 2028-06-14	FSS
DERMELEVE 0.2% CREAM,TOP	Golden State Medical Supply, Inc.	81507-0002-01	30GM	8.39	0.27967	GM	2024-05-15 - 2028-06-14	FSS
DERMELEVE 0.2% CREAM,TOP	Golden State Medical Supply, Inc.	81507-0002-02	60GM	13.99	0.23317	GM	2024-05-15 - 2028-06-14	FSS

Last updated: July 11, 2026

Aluminum (Active Ingredient) Drug Market Analysis and Price Projections

No market analysis or price projections can be produced for “ALUMINUM” as a drug name because “aluminum” is a chemical element used across multiple pharmaceutical product categories (not a single FDA-approved drug substance with a unified NDC, regulatory status, and commercial history). Without a specific drug product name, salt/formulation, route, and market jurisdiction, any pricing or forecast would not be grounded in identifiable branded/generic endpoints.

Given the requirement to produce complete and accurate hard data, no response is provided.

Key Takeaways

• “ALUMINUM” is not a sufficient identifier for market sizing, competitive landscape, exclusivity, or price forecasting.
• Pricing projections require a specific aluminum-containing drug product (e.g., active moiety as a salt, dosage form, and FDA/market identity).

FAQs

1. Which aluminum-containing drugs have US FDA approvals and measurable pricing histories?
2. How do aluminum salt formulations (e.g., hydroxide, phosphate binders) change competitive pricing dynamics?
3. What drives price volatility for aluminum-based therapies in dialysis and GI indications?
4. When do aluminum product patents and exclusivities expire for specific branded products?
5. What generic entry risks exist for aluminum-based phosphate binders and antacids?

References

No sources cited.